加载中
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
前收盘价
US$2.54
+US$0.01 · +0.40%
盘中时间采用ET。市场数据可能有所延迟。
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
日内区间
当前US$2.54
52周区间
当前US$2.54
盘中时间采用ET。市场数据可能有所延迟。
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
日内区间
当前US$2.54
52周区间
当前US$2.54
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 1600万 USD | — | — | — |
| 销货成本 | 2.48万 USD | — | — | — | — |
| 毛利 | −2.48万 USD | 1600万 USD | — | — | — |
| 研究与开发 | 1078.04万 USD | 489.69万 USD | 402.7万 USD | 344.89万 USD | 535.03万 USD |
| 销售、一般及管理费用 | 574.51万 USD | 554.23万 USD | 466.31万 USD | 827.8万 USD | 532.36万 USD |
| 营业费用 | 943.44万 USD | 1148.97万 USD | 1258.69万 USD | 1230.95万 USD | 1423.58万 USD |
| 利息收入 | 89.4万 USD | 125.28万 USD | 17.4万 USD | 5.69万 USD | 1141 USD |
| 利息支出 | 2万 USD | 2.14万 USD | 1.11万 USD | 8599 USD | 6851 USD |
| 折旧和摊销 | 2.48万 USD | 1.92万 USD | 5.18万 USD | 4.16万 USD | 4.53万 USD |
| 营业利润 | −945.92万 USD | 451.03万 USD | −1258.69万 USD | −1230.95万 USD | −1423.58万 USD |
| 净利润 | −1083.52万 USD | 359.47万 USD | −1251.39万 USD | −1358.36万 USD | −1377.07万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Extended Market ETFVXF5.52万0.00%954亿 USD0.05%US$235+0.80%
U.S. Vector Equity Portfolio ETF Class SharesDXUV9846.730.00%61.81亿 USD0.26%US$68.28+0.25%
Dimensional - US Core Equity 2 ETFDFAC8810.10.00%885.96亿 USD0.21%US$45.33+0.49%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR3950.740.00%455.91亿 USD0.17%US$84.44+0.44%
Dimensional - US Sustainability Core 1 ETFDFSU3087.30.00%23.92亿 USD0.15%US$48.11+0.48%Vanguard Extended Market ETFVXFU.S. Vector Equity Portfolio ETF Class SharesDXUVDimensional - US Core Equity 2 ETFDFACU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Sustainability Core 1 ETFDFSUAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
